A Case of Tumor Lysis Syndrome in a Patient with Pancreatic Adenocarcinoma Treated with Low-Dose Gemcitabine

Background: Tumor lysis syndrome (TLS) is a common adverse consequence of treatment of high-grade hematologic malignancies that has been known to occur rarely in some solid tumors, including small cell lung cancer, breast cancer, colorectal cancer, neuroblastoma, ovarian cancer, and hepatocellular carcinoma. Case Report: We present a case of TLS in a patient with pancreatic adenocarcinoma treated with one small dose of gemcitabine. To our knowledge, this phenomenon has only been described once prior in the medical literature and never with a reduced dose of chemotherapy. Conclusion: This case reveals the need for heightened awareness of TLS in patients with solid tumors, especially in patients with pancreatic adenocarcinoma.